Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NMRA Neumora Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: NMRA
Price (delayed)
$0.78
Market cap
$126.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
-$971,621
Highlights
The debt has plunged by 79% YoY and by 49% from the previous quarter
The company's EPS rose by 43% YoY but it fell by 5% QoQ
Neumora Therapeutics's quick ratio has decreased by 49% YoY and by 15% QoQ
Neumora Therapeutics's equity has decreased by 46% YoY and by 20% QoQ
Key stats
What are the main financial stats of NMRA
Market
Valuations
Earnings
Shares outstanding
161.75M
Market cap
$126.16M
Enterprise value
-$971,621
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$274.33M
Net income
-$258.06M
EBIT
-$257.78M
EBITDA
-$253.77M
Free cash flow
-$199.43M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$1.24
Book value per share
$1.41
Revenue per share
$0
TBVPS
$1.59
Total assets
$256.75M
Total liabilities
$28.38M
Debt
$938,000
Equity
$228.36M
Working capital
$226.48M
Debt to equity
0
Current ratio
8.98
Quick ratio
8.83
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-77.6%
Return on equity
-84.8%
Return on invested capital
-195.8%
Return on capital employed
-112.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NMRA stock price
How has the Neumora Therapeutics stock price performed over time
Intraday
-1.64%
1 week
-15.37%
1 month
11.17%
1 year
-91.48%
YTD
-92.64%
QTD
-22%
Financial performance
How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$274.33M
Net income
-$258.06M
Gross margin
N/A
Net margin
N/A
The net income has declined by 6% since the previous quarter
Neumora Therapeutics's operating income has decreased by 4.1% QoQ
Price vs fundamentals
How does NMRA's price correlate with its fundamentals
Growth
What is Neumora Therapeutics's growth rate over time
Valuation
What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
0.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 43% YoY but it fell by 5% QoQ
The stock's P/B is 87% below its last 4 quarters average of 4.3
Neumora Therapeutics's equity has decreased by 46% YoY and by 20% QoQ
Efficiency
How efficient is Neumora Therapeutics business performance
The ROA has contracted by 41% YoY and by 21% from the previous quarter
NMRA's return on invested capital is down by 35% since the previous quarter and by 14% year-on-year
The ROE has grown by 25% YoY but it has contracted by 23% from the previous quarter
Dividends
What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NMRA.
Financial health
How did Neumora Therapeutics financials performed over time
NMRA's current ratio has dropped by 50% year-on-year and by 15% since the previous quarter
Neumora Therapeutics's quick ratio has decreased by 49% YoY and by 15% QoQ
The debt is 100% less than the equity
Neumora Therapeutics's debt to equity has shrunk by 100% QoQ and by 100% YoY
The debt has plunged by 79% YoY and by 49% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.